A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+metastatic breast cancer (MBC)

被引：0

作者：

Borges, Virginia F. ^{[1
]}

Hamilton, Erika ^{[2
,3
]}

Yardley, Denise A. ^{[2
,3
]}

Chaves, Jorge ^{[4
]}

Aucoin, Nathalie ^{[5
]}

Ferrario, Cristiano ^{[6
]}

Walker, Luke ^{[7
]}

Krop, Ian ^{[8
]}

机构：

[1] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Tennessee Oncol PLLC, Nashville, TN USA

[4] Northwest Med Specialties, Tacoma, WA USA

[5] Hop Cite de la Sante, Laval, PQ, Canada

[6] Jewish Gen Hosp, Montreal, PQ, Canada

[7] Oncothyreon Inc, Seattle, WA USA

[8] Dana Farber Canc Inst, Boston, MA USA

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P4-15-08

引用

页数：2

共 50 条

[21] Efficacy results of a phase lb study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+metastatic breast cancer (MBC), including patients (pts) with brain metastases.
Borges, Virginia F.
Ferrario, Cristiano
Aucoin, Nathalie
Falkson, Carla Isadora
Khan, Qamar J.
Krop, Ian E.
Welch, Stephen
Bedard, Philippe L.
Conlin, Alison Katherine
Chaves, Jorge
Walker, Luke N.
Hamilton, Erika Paige
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[22] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
Boyraz, Baris
Sendur, Mehmet A. N.
Aksoy, Sercan
Babacan, Taner
Roach, Emir C.
Kizilarslanoglu, Muhammet C.
Petekkaya, Ibrahim
Altundag, Kadri
CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
[23] Ado-trastuzumab emtansine (T-DM1) is effective against established HER2-positive breast cancer brain metastases in mice
Askoxylakis, V.
Ferraro, G.
Kodack, D.
Badeaux, M.
Jain, R.
CANCER RESEARCH, 2016, 76
[24] LONG TIME RESPONSE WITH ADO-TRASTUZUMAB EMTANSINE (T-DM1) IN A RECURRENT METASTATIC BREAST CANCER
Manthri, S.
Singal, S.
Youssef, B.
Chakraborthy, K.
JOURNAL OF INVESTIGATIVE MEDICINE, 2019, 67 (02) : 435 - 435
[25] A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+metastatic colorectal cancer (mCRC) (MOUNTAINEER).
Strickler, John H.
Niedzwiecki, Donna
Zemla, Tyler
Cercek, Andrea
Fakih, Marwan
Ng, Kimmie
Sanchez, Federico Augusto
Wu, Christina Sing-Ying
Peterson, Scott
Bandel, Lorelei
Grothey, Axel
Bekaii-Saab, Tanios S.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[26] Liquid biopsy and Ado-trastuzumab emtansine (T-DM1): drug-resistance traits in the blood of HER2-positive metastatic breast cancer patients
Fabi, Alessandra
Allegretti, Matteo
Giordani, Elena
Ferretti, Gianluigi
Arpino, Grazia
Zambelli, Alberto
Omarini, Claudia
Paris, Ida
Botticelli, Andrea
Bria, Emilio
Palazzo, Antonella
Gori, Stefania
Cognetti, Francesco
Giacomini, Patrizio
CANCER RESEARCH, 2023, 83 (05)
[27] Metastatic HER2-positive Breast Cancer New Perspectives with Trastuzumab Emtansine (T-DM1)
Satzger, Ulla
ONKOLOGIE, 2013, 36 (09): : 525 - 525
[28] Safety, efficacy and survival outcome of Ado-trastuzumab emtansine (T-DM1) in patients with metastatic HER2-positive breast cancer: An Indian experience.
Gogia, Ajay
Gupta, Anshul
Deo, S. V. S.
Sharma, Dayanand
Mathur, Sandeep
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[29] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
Thibault, C.
ONCOLOGIE, 2013, 15 (02) : 126 - 127
[30] Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-PositiveMetastatic Breast Cancer A Phase 1b Clinical Trial
Borges, Virginia F.
Ferrario, Cristiano
Aucoin, Nathalie
Falkson, Carla
Khan, Qamar
Krop, Ian
Welch, Stephen
Conlin, Alison
Chaves, Jorge
Bedard, Philippe L.
Chamberlain, Marc
Gray, Todd
Vo, Alex
Hamilton, Erika
JAMA ONCOLOGY, 2018, 4 (09) : 1214 - 1220

← 1 2 3 4 5 →